Endra Life Sciences Inc (NDRA)

$4.57 +0.03 (0.77%)
Market Cap 5.77M
Revenue (ttm) 0.00
Net Income (ttm) -7.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,000
Avg Vol 34,898
Day's Range N/A - N/A
Shares Out 1.27M
Stochastic %K 51%
Beta -0.05
Analysts Sell
Price Target $25.00

Company Profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and ti...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 734 335 0468
Address:
3600 Green Court, Suite 350, Ann Arbor, United States
ZacksResearch
ZacksResearch Aug. 6 at 3:44 PM
$NDRA valuation check 📊 NDRA currently trades at 3.6x forward sales, well below its recent peak valuation of 6.3x despite advancing toward commercialization of its TAEUS liver imaging platform. As regulatory and commercial milestones begin to unfold, any improvement in execution could support a re-rating toward historical multiples. The current valuation leaves room for upside if the company delivers on adoption and revenue growth. Find more on $NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39150&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39150
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 12:53 PM
$NDRA: What investors should watch heading into Q2 earnings 📊 ENDRA continued operating as a pre-revenue company in Q1 while advancing its TAEUS ultrasound technology toward commercialization. 💰 Net loss came in at $1.3M, or $1.09 per share, versus $1.0M, or $1.86 per share, in the prior-year quarter. 🏥 The quarter was centered on regulatory execution, technology development and laying the groundwork for future market adoption. 👀 As Q2 results approach, investors will be focused on regulatory progress, commercialization timelines, cash runway and any updates on strategic partnerships. Find more on $NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39050&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39050
0 · Reply
ZacksResearch
ZacksResearch Jul. 23 at 2:18 PM
$NDRA: looking back at the Q1 development story 📊 📈 The company remained in its pre-revenue stage as it continued advancing its TAEUS platform. 💵 Net loss totaled $1.3M, or $1.09 per share, compared with $1.0M, or $1.86 per share, a year earlier. 🏥 Management has remained focused on regulatory progress and preparing TAEUS for broader market adoption. 👀 With Q2 earnings due next month, investors will be looking for updates on regulatory milestones, commercialization plans and financing. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38941&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38941
0 · Reply
Reacting_
Reacting_ Jul. 22 at 7:31 PM
$NDRA
0 · Reply
Buylocal
Buylocal Jul. 21 at 10:35 PM
$NDRA looks like it’s time to increase share count. Been claiming all the other data for 5 years. FDA not buying it.
0 · Reply
Gainprofit
Gainprofit Jul. 21 at 3:06 PM
$NDRA 👀 still watching this one moving slowly
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 12:02 PM
$NDRA Q1 2026 Financial Highlights: • Cash used in operations improved to $1.1M from $1.3M in Q1 2025. • Operating expenses rose to $2.2M from $1.5M, while net loss widened to $1.3M from $1.0M. • Ended Q1 with $356K in cash and cash equivalents, plus ~$2.4M held in its Digital Asset Treasury. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38835&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38835
0 · Reply
ZacksResearch
ZacksResearch Jul. 15 at 12:32 PM
$NDRA reports another encouraging clinical milestone. 🩺 TAEUS Liver demonstrated MRI-like accuracy in a multi-site validation study. 📊 Key highlights: ✅ 0.90 correlation with MRI-PDFF ✅ AUROC of 0.95–0.99 ✅ ~3% mean error ✅ High reproducibility (ICC 0.89) ✅ Performance remained consistent across operators, sites and BMI ranges. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38787&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38787
0 · Reply
Gainprofit
Gainprofit Jul. 14 at 10:20 PM
$NDRA Still keeping an eye on this one in the coming days 👀
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 10:16 PM
$NDRA ✨
0 · Reply
Latest News on NDRA
ASP Isotopes Issues Letter to Shareholders

Aug 4, 2026, 8:00 AM EDT - 2 days ago

ASP Isotopes Issues Letter to Shareholders

ASPI

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

Jul 17, 2026, 10:35 AM EDT - 20 days ago

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

ASPI

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

Jul 2, 2026, 4:07 PM EDT - 5 weeks ago

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

BOLD

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Jun 25, 2026, 9:51 AM EDT - 6 weeks ago

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

ASPI

ENDRA Life Sciences Inc trading resumes

2026-06-25T13:40:30.000Z - 6 weeks ago

ENDRA Life Sciences Inc trading resumes

ENDRA Life Sciences Inc trading halted, volatility trading pause

2026-06-25T13:36:02.000Z - 6 weeks ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

ASP Isotopes announces proposed merger of Noble Africa, ENDRA Life Sciences

2026-06-25T13:35:09.000Z - 6 weeks ago

ASP Isotopes announces proposed merger of Noble Africa, ENDRA Life Sciences

ASPI

Endra Life Sciences reports Q1 EPS ($1.09) vs. ($1.86) last year

2026-05-18T12:16:31.000Z - 2 months ago

Endra Life Sciences reports Q1 EPS ($1.09) vs. ($1.86) last year

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026, 8:00 AM EDT - 2 months ago

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

ENDRA Life Sciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

ENDRA Life Sciences Quarterly report: Q1 2026

Endra Life Sciences reports multi-site validation of TAEUS Liver device

2026-05-14T16:56:55.000Z - 3 months ago

Endra Life Sciences reports multi-site validation of TAEUS Liver device

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

May 14, 2026, 8:00 AM EDT - 3 months ago

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

ENDRA Life Sciences Inc trading halted, volatility trading pause

2026-05-13T19:50:08.000Z - 3 months ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

ENDRA Life Sciences Inc trading resumes

2026-05-13T19:48:18.000Z - 3 months ago

ENDRA Life Sciences Inc trading resumes

Endra Life Sciences reports Q4 EPS ($8.93) vs ($56.94) last year

2026-03-31T20:12:41.000Z - 4 months ago

Endra Life Sciences reports Q4 EPS ($8.93) vs ($56.94) last year

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 31, 2026, 4:05 PM EDT - 4 months ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 4 months ago

ENDRA Life Sciences Annual report: Q4 2025

ENDRA Life Sciences Earnings release: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 4 months ago

ENDRA Life Sciences Earnings release: Q4 2025

Endra Life Sciences initiates review of strategic alternatives

2026-03-25T12:06:25.000Z - 4 months ago

Endra Life Sciences initiates review of strategic alternatives

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

Endra Life Sciences announces favorable TAEUS liver device study results

2026-02-26T14:33:33.000Z - 5 months ago

Endra Life Sciences announces favorable TAEUS liver device study results

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

Feb 26, 2026, 8:00 AM EST - 5 months ago

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

Endra Life Sciences announces results from Taeus Liver device feasibility study

2025-12-04T13:20:28.000Z - 8 months ago

Endra Life Sciences announces results from Taeus Liver device feasibility study

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Dec 4, 2025, 8:00 AM EST - 8 months ago

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Nov 20, 2025, 8:00 AM EST - 9 months ago

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Nov 17, 2025, 8:00 AM EST - 9 months ago

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

ENDRA Life Sciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

ENDRA Life Sciences Earnings release: Q3 2025

ENDRA Life Sciences Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

ENDRA Life Sciences Quarterly report: Q3 2025

Endra Life Sciences commences staking of HYPE digital asset holdings

2025-11-13T14:25:52.000Z - 9 months ago

Endra Life Sciences commences staking of HYPE digital asset holdings

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Nov 13, 2025, 8:00 AM EST - 9 months ago

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Endra Life Sciences files to sell 2.68M shares of common stock for holders

2025-11-06T22:05:26.000Z - 9 months ago

Endra Life Sciences files to sell 2.68M shares of common stock for holders

ENDRA Life Sciences Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 9 months ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Oct 23, 2025, 8:00 AM EDT - 10 months ago

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 10 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Oct 13, 2025, 8:00 AM EDT - 10 months ago

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Endra Life Sciences reports Q2 EPS ($1.71) vs. (8c) last year

2025-08-14T20:15:23.000Z - 1 year ago

Endra Life Sciences reports Q2 EPS ($1.71) vs. (8c) last year

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

ENDRA Life Sciences Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q2 2025

ENDRA Life Sciences Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

ENDRA Life Sciences Quarterly report: Q2 2025

ENDRA Life Sciences Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Registration statement: Registration Filing

Endra Life Sciences files to sell 15.7M shares of common stock

2025-07-09T13:15:12.000Z - 1 year ago

Endra Life Sciences files to sell 15.7M shares of common stock

ENDRA Life Sciences Registration statement: Registration Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

Jun 16, 2025, 8:00 AM EDT - 1 year ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

Endra Life Sciences reports Q1 EPS ($1.86) vs ($449.58) last year

2025-05-15T20:15:45.000Z - 1 year ago

Endra Life Sciences reports Q1 EPS ($1.86) vs ($449.58) last year

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

ENDRA Life Sciences Quarterly report: Q1 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

ENDRA Life Sciences Quarterly report: Q1 2025

ENDRA Life Sciences Earnings release: Q1 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q1 2025

ENDRA Life Sciences Inc trading resumes

2025-05-09T14:02:48.000Z - 1 year ago

ENDRA Life Sciences Inc trading resumes

ENDRA Life Sciences Inc trading halted, volatility trading pause

2025-05-09T13:58:10.000Z - 1 year ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

ENDRA Life Sciences Earnings release: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q4 2024

ENDRA Life Sciences Annual report: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

ENDRA Life Sciences Annual report: Q4 2024

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:05 AM EDT - 1 year ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Inc trading resumes

2024-11-29T16:15:26.000Z - 1 year ago

ENDRA Life Sciences Inc trading resumes

ENDRA Life Sciences Inc trading halted, volatility trading pause

2024-11-29T16:10:16.000Z - 1 year ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 22, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Quarterly report: Q3 2024

Nov 15, 2024, 4:00 PM EST - 1 year ago

ENDRA Life Sciences Quarterly report: Q3 2024

ENDRA Life Sciences Earnings release: Q3 2024

Nov 15, 2024, 4:00 PM EST - 1 year ago

ENDRA Life Sciences Earnings release: Q3 2024

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 15, 2024, 9:24 AM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Nov 6, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Oct 22, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

ENDRA Life Sciences Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Sep 6, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 28, 2024, 4:17 PM EDT - 2 years ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Earnings Call Transcript: Q2 2024

Aug 22, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q2 2024

ENDRA Life Sciences Quarterly report: Q2 2024

Aug 22, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Quarterly report: Q2 2024

ENDRA Life Sciences Earnings release: Q2 2024

Aug 22, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings release: Q2 2024

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 22, 2024, 4:14 PM EDT - 2 years ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Announces Reverse Stock Split

Aug 16, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Announces Reverse Stock Split

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ENDRA Life Sciences Announces Leadership Changes

Aug 13, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Announces Leadership Changes

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Aug 7, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

ENDRA Life Sciences Proxy statement: Proxy Filing

Jul 17, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 25, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 25, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 12, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:21 AM EDT - 2 years ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

Jun 4, 2024, 9:06 AM EDT - 2 years ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

ENDRA Life Sciences Registration statement: Registration Filing

May 31, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Provides Update Following In-person Meeting with FDA

May 20, 2024, 8:00 AM EDT - 2 years ago

ENDRA Provides Update Following In-person Meeting with FDA

ENDRA Life Sciences Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q1 2024

ENDRA Life Sciences Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Quarterly report: Q1 2024

ENDRA Life Sciences Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings release: Q1 2024

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 14, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Registration statement: Registration Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

May 2, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

ENDRA Life Sciences Registration statement: Registration Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q4 2023

ENDRA Life Sciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Annual report: Q4 2023

ENDRA Life Sciences Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings release: Q4 2023

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

ENDRA Life Sciences Registration statement: Registration Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 27, 2024, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Installs First TAEUS System in the UK

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 21, 2024, 8:00 AM EST - 2 years ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Feb 14, 2024, 8:30 AM EST - 2 years ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

ENDRA Life Sciences Registration statement: Registration Filing

Feb 14, 2024, 7:00 AM EST - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 29, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 27, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

ENDRA Life Sciences Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q3 2023

ENDRA Life Sciences Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Quarterly report: Q3 2023

ENDRA Life Sciences Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Earnings release: Q3 2023

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 8, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Sep 7, 2023, 8:00 AM EDT - 3 years ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

ZacksResearch
ZacksResearch Aug. 6 at 3:44 PM
$NDRA valuation check 📊 NDRA currently trades at 3.6x forward sales, well below its recent peak valuation of 6.3x despite advancing toward commercialization of its TAEUS liver imaging platform. As regulatory and commercial milestones begin to unfold, any improvement in execution could support a re-rating toward historical multiples. The current valuation leaves room for upside if the company delivers on adoption and revenue growth. Find more on $NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39150&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39150
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 12:53 PM
$NDRA: What investors should watch heading into Q2 earnings 📊 ENDRA continued operating as a pre-revenue company in Q1 while advancing its TAEUS ultrasound technology toward commercialization. 💰 Net loss came in at $1.3M, or $1.09 per share, versus $1.0M, or $1.86 per share, in the prior-year quarter. 🏥 The quarter was centered on regulatory execution, technology development and laying the groundwork for future market adoption. 👀 As Q2 results approach, investors will be focused on regulatory progress, commercialization timelines, cash runway and any updates on strategic partnerships. Find more on $NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39050&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39050
0 · Reply
ZacksResearch
ZacksResearch Jul. 23 at 2:18 PM
$NDRA: looking back at the Q1 development story 📊 📈 The company remained in its pre-revenue stage as it continued advancing its TAEUS platform. 💵 Net loss totaled $1.3M, or $1.09 per share, compared with $1.0M, or $1.86 per share, a year earlier. 🏥 Management has remained focused on regulatory progress and preparing TAEUS for broader market adoption. 👀 With Q2 earnings due next month, investors will be looking for updates on regulatory milestones, commercialization plans and financing. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38941&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38941
0 · Reply
Reacting_
Reacting_ Jul. 22 at 7:31 PM
$NDRA
0 · Reply
Buylocal
Buylocal Jul. 21 at 10:35 PM
$NDRA looks like it’s time to increase share count. Been claiming all the other data for 5 years. FDA not buying it.
0 · Reply
Gainprofit
Gainprofit Jul. 21 at 3:06 PM
$NDRA 👀 still watching this one moving slowly
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 12:02 PM
$NDRA Q1 2026 Financial Highlights: • Cash used in operations improved to $1.1M from $1.3M in Q1 2025. • Operating expenses rose to $2.2M from $1.5M, while net loss widened to $1.3M from $1.0M. • Ended Q1 with $356K in cash and cash equivalents, plus ~$2.4M held in its Digital Asset Treasury. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38835&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38835
0 · Reply
ZacksResearch
ZacksResearch Jul. 15 at 12:32 PM
$NDRA reports another encouraging clinical milestone. 🩺 TAEUS Liver demonstrated MRI-like accuracy in a multi-site validation study. 📊 Key highlights: ✅ 0.90 correlation with MRI-PDFF ✅ AUROC of 0.95–0.99 ✅ ~3% mean error ✅ High reproducibility (ICC 0.89) ✅ Performance remained consistent across operators, sites and BMI ranges. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-38787&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38787
0 · Reply
Gainprofit
Gainprofit Jul. 14 at 10:20 PM
$NDRA Still keeping an eye on this one in the coming days 👀
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 10:16 PM
$NDRA ✨
0 · Reply
Cup_of_Joe_Trader
Cup_of_Joe_Trader Jul. 14 at 12:55 PM
$NDRA Is there news?
1 · Reply
MrGreenth
MrGreenth Jul. 10 at 12:14 AM
$NDRA 7-8$ on deck
0 · Reply
Budman10
Budman10 Jul. 9 at 8:14 PM
$NDRA Beware, heavy reverse stock split is imminent
1 · Reply
Gainprofit
Gainprofit Jul. 9 at 3:04 PM
$NDRA 👀
0 · Reply
JCDollars
JCDollars Jul. 9 at 11:47 AM
$NDRA why we popping ??
0 · Reply
ZacksResearch
ZacksResearch Jul. 7 at 12:33 PM
$NDRA pivots into helium with a Nasdaq merger 🚀 🤝 ENDRA will merge with Noble Africa, ASP Isotopes' helium subsidiary 💰 The deal includes a $50M private placement to fund project development 🌍 Noble Africa holds Renergen's Virginia Gas Project, a globally significant helium asset 📈 The combined company plans to list on Nasdaq under the ticker $NOBA 📊 $NDRA is up 4.2% YTD despite the strategic transformation ❓Could this merger unlock long-term value, or is execution now the biggest challenge? Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?q=ndra&art_rec=quote-stock_overview-search_filter-zcom-NDRA&cid=sm-stocktwits-0-quote_overview-oc-38663&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_38663
0 · Reply
hotstocknews291
hotstocknews291 Jul. 6 at 12:39 PM
$NDRA $SLS Please avoid the post❌
0 · Reply
hotstocknews291
hotstocknews291 Jul. 6 at 12:21 PM
$NDRA VS $SLS The stock experienced large price swings, which is common for low-market-cap biotech companies. Trading volume increased on several sessions, indicating active interest from short-term traders. The company's valuation remains very small (around $5.7 million), making the share price highly sensitive to news and trading activity. Bullish factors Increased trading volume and retail interest. Any future clinical, regulatory, or financing news could have an outsized impact on the stock price. Bearish factors The company is still pre-profit and continues to face financing and execution risks. Micro-cap biotech stocks like NDRA can be extremely volatile and may experience sharp declines if positive catalysts fail to materialize. Overall outlook Short-term: Neutral to speculative. Expect continued volatility. Long-term: Dependent on future clinical progress, regulatory milestones, and the company's ability to secure funding.
3 · Reply
Budman10
Budman10 Jun. 26 at 12:31 PM
$NDRA Assuming a 350 million market cap for the new company, NOBA, the price would be a double from here. Better to own ASPI I think though.
0 · Reply
Buylocal
Buylocal Jun. 25 at 9:09 PM
$NDRA is there a go fund me for funeral flowers?
0 · Reply